Low-Intensity Shockwave Therapy / GAINSWave
Li-ESWT (low-intensity extracorporeal shockwave therapy)
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not FDA-cleared for ED specifically
Reference only. Not medical advice.
What can go wrong
Generally low-risk and non-invasive; transient discomfort is the main reported effect. The principal concern is not physical harm but financial and expectation harm: durability of benefit is unproven, optimal protocols are not standardized, and commercial providers often charge $3,000-$6,000 for treatment packages whose long-term efficacy the evidence does not yet establish.
This is something to take to a clinician. The Atlas can tell you what is known about low-intensity shockwave therapy / gainswave in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Low-intensity extracorporeal shockwave therapy applies acoustic pressure waves to penile tissue, proposed to stimulate neovascularization and improve endothelial function in vasculogenic ED. Multiple RCTs show improvement, and it is widely used in Europe, but it is not FDA-cleared for ED specifically. GAINSWave is the dominant US commercial brand, whose marketing significantly outpaces the published evidence on durability and protocol.
Promising mechanism, real RCTs, and marketing well ahead of the evidence.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Acoustic shockwaves are hypothesized to trigger mechanotransduction, releasing angiogenic growth factors (VEGF, eNOS upregulation) that promote new blood vessel formation and recruit endothelial progenitor cells, potentially addressing the vascular root of ED rather than only the symptom.
What people get wrong
Often saidShockwave permanently cures ED
ActuallyRCTs show improvement, but long-term durability is unclear and benefit may wane. Marketing claims of a permanent cure run ahead of the published data.
Who profits, and who pushes back
GAINSWave-affiliated clinicians and influencers
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
GAINSWave operates a substantial provider and influencer program. Identified partners and 'recommended providers' have a PAID RELATIONSHIP / commercial stake in the brand and should be read as advertising, not independent endorsement.
At a glance
- Proposed mechanism
- Neovascularization, endothelial repair
- FDA status for ED
- Not cleared
- European use
- Widespread
- US commercial brand
- GAINSWave
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Low-Intensity Shockwave Therapy / GAINSWave. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.